CD274 and adenocarcinoma: ObRR: 9.9% among all patients, 14.3% among patients with ESCC, 5.2% among patients with adenocarcinoma, 13.8% among patients with PD‐L1–positive tumors, 6.3% among patients with PD‐L1‐negative tumors